Misbah Sehar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Misbah Sehar has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Po-Kai Chuang
Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan
3 shared publications - Yung-Kuo Lee
Institute of Medical Science and Technology, National Sun Yat-sen University, Kaohsiung, Taiwan
3 shared publications - Chien-Han Yuan
Medical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, National Defense Medical University, Kaohsiung 80284, Taiwan
1 shared publication - Chih-Hsuan Chang
Medical Laboratory, Medical Education and Research Center, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan
1 shared publication - Chih-Yang Wang
PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
1 shared publication - Ching-Cheng Hsu
Center for Regenerative Medicine, University of South Florida Health Heart Institute, Tampa, U.S.A.
1 shared publication
Latest Publications
- 24 September 2025
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 25 (2) , 1647-1680
A comprehensive review of the phytochemical and pharmacological attributes of Coronopus didymus
- 24 September 2025
- Published by Springer Nature in Phytochemistry Reviews
- Vol. 25 (2) , 1647-1680
A comprehensive review of the phytochemical and pharmacological attributes of Coronopus didymus
- Open Access
- 12 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13353
Acetylated Globotetraose (Ac-Gb4) Suppresses Triple-Negative Breast Cancer Through FAK/AKT Signaling Pathway
Triple-negative breast cancer (TNBC) remains a significant therapeutic challenge due to its unresponsiveness to hormone and HER2-targeted treatments. This study investigated the potential of acetylated globotetraose (Ac-Gb4) as a novel therapeutic approach targeting glycolipid-mediated signaling in breast cancer cells. We synthesized acetylated globotetraose (Gb4) to enhance its membrane permeability while preserving its biological recognition properties. Flow cytometry analysis revealed that Ac-Gb4 treatment significantly decreased SSEA3 and SSEA4 expression in MDA-MB-231 breast cancer cells, which are Globo-H-negative cells. Notably, Ac-Gb4 demonstrated selective cytotoxicity against cancer cells by significantly reducing proliferation and inducing apoptosis in MDA-MB-231 cells while sparing hTERT-HME1 normal breast epithelial cells. Mechanistic studies through Western blot analysis revealed that Ac-Gb4 simultaneously modulated multiple signaling pathways, including FAK cleavage, reduced AKT expression, and increased caspase-3 activation, particularly at the 4 mM concentration. These molecular changes correlated with decreased cancer cell invasion capability in a dose-dependent manner. Our findings demonstrated that Ac-Gb4 effectively targeted breast cancer cells through the modulation of critical signaling pathways involved in cell survival and invasion while maintaining a minimal impact on normal cells. This anti-cancer activity suggests that Ac-Gb4 represents a promising therapeutic candidate for breast cancer treatment, particularly for aggressive subtypes such as TNBC.
- 12 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13353
Open AccessAcetylated Globotetraose (Ac-Gb4) Suppresses Triple-Negative Breast Cancer Through FAK/AKT Signaling Pathway
Triple-negative breast cancer (TNBC) remains a significant therapeutic challenge due to its unresponsiveness to hormone and HER2-targeted treatments. This study investigated the potential of acetylated globotetraose (Ac-Gb4) as a novel therapeutic approach targeting glycolipid-mediated signaling in breast cancer cells. We synthesized acetylated globotetraose (Gb4) to enhance its membrane permeability while preserving its biological recognition properties. Flow cytometry analysis revealed that Ac-Gb4 treatment significantly decreased SSEA3 and SSEA4 expression in MDA-MB-231 breast cancer cells, which are Globo-H-negative cells. Notably, Ac-Gb4 demonstrated selective cytotoxicity against cancer cells by significantly reducing proliferation and inducing apoptosis in MDA-MB-231 cells while sparing hTERT-HME1 normal breast epithelial cells. Mechanistic studies through Western blot analysis revealed that Ac-Gb4 simultaneously modulated multiple signaling pathways, including FAK cleavage, reduced AKT expression, and increased caspase-3 activation, particularly at the 4 mM concentration. These molecular changes correlated with decreased cancer cell invasion capability in a dose-dependent manner. Our findings demonstrated that Ac-Gb4 effectively targeted breast cancer cells through the modulation of critical signaling pathways involved in cell survival and invasion while maintaining a minimal impact on normal cells. This anti-cancer activity suggests that Ac-Gb4 represents a promising therapeutic candidate for breast cancer treatment, particularly for aggressive subtypes such as TNBC.